| GENMAB AS DK 1 |
| Dänemark |
| Gesundheit |
| DK0010272202 / 565131 |
| GE9 (Frankfurt) |
| FRA:GE9, ETR:GE9, GE9:GR |
| - |
| https://www.genmab.com/ |
|
Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of antibody-based therapeutics primarily for cancer and other serious diseases. Founded in 1998, it focuses on innovative human ..
>Volltext.. |
| 13552.32 Mio. EUR |
| 16863.54 Mio. EUR |
| 3403.49 Mio. EUR |
| 1197.22 Mio. EUR |
| 719.29 Mio. EUR |
| 11.69 EUR |
| 4700.69 Mio. EUR |
| 1336.15 Mio. EUR |
| 789.41 Mio. EUR |
| 1.29 |
| 11.53% |
| -33.03% |
| - |
| - |
| - |
| - |
| GENMAB |
| 30.06.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|